• Trendlyne logo
  • Markets
  • Alerts
  • F&O
  • MF
  • Reports
  • Screeners
  • Subscribe
  • Superstars
  • Portfolio
  • Watchlist
  • Insider Trades
  • Results
  • Data Downloader
  • Events Calendar
  • What's New
  • Explore
  • FAQs
  • Widgets
More
    Search stocks
    IND USA
    IND
    IND
    IND
    USA
    • Stocks
    • Futures & Options
    • Mutual Funds
    • News
    • Fundamentals
    • Reports
    • Corporate Actions
    • Alerts
    • Shareholding
    logo
    Anthem Biosciences Ltd.
    14 Jul 2025
    833.50
    1.53%
    Anthem Biosciences IPO subscribed 73 pc on Day 1 of offer
    Business Standard
    The initial public offer of Anthem Biosciences Ltd got subscribed 73 per cent on the first day of share sale on Monday. The initial share sale received bids for 3,21,13,406 shares against 4,40,70,682 shares on offer, according to NSE data. Non-institutional Investors category garnered 1.55 times subscription, while the quota for Retail Individual Investors (RIIs) got subscribed 58 per cent. The portion for Qualified Institutional Buyers (QIBs) received 37 per cent subscription. Anthem Biosciences has raised Rs 1,016 crore from anchor investors. The Rs 3,395-crore IPO of the Bengaluru-based firm will close on July 16. The price band has been fixed at Rs 540-570 per share. Since the IPO is entirely an offer-for-sale (OFS), the company will not receive any funds from the issue, and the proceeds will go to the selling shareholders. Anthem is into innovation-driven and technology-focused Contract Research, Development and Manufacturing Organization (CRDMO) with fully integrated operat
    Copy LinkShare onShare on Share on Share on
    Anthem Biosciences Ltd. is trading above all available SMAs
    logo
    Neuland Laboratories Ltd.
    14 Jul 2025
    Analyst Buy
    16049.00
    3.18%
    Neuland Laboratories shares jump 12% ahead of final dividend
    Neuland Laboratories shares jump 12% ahead of final dividend
    Economic Times
    Neuland Laboratories shares are experiencing a surge, trading 12% higher. This increase comes as investors anticipate a final dividend of Rs 12 per share. The record date for dividend eligibility is July 18, 2025. Technically, the stock shows a strong bullish trend. It trades above all analyzed Simple Moving Averages. The Relative Strength Index indicates neither oversold nor overbought conditions.
    Copy LinkShare onShare on Share on Share on
    Neuland Laboratories Ltd. is trading at high day volume of 157.0K.
    Mukul Agrawal portfolio pharmaceutical stock surges 10% in weak market
    Business Standard | 14 Jul 2025
    logo
    Wockhardt Ltd.
    14 Jul 2025
    1518.00
    -0.61%
    Wockhardt shares rise 2% after exiting US generics business
    Business Standard
    Wockhardt shares rose 2 per cent after it decided to exit the US generic pharmaceutical segment after incurring consistent losses
    Copy LinkShare onShare on Share on Share on
    Wockhardt Ltd. has an average target of 1870.00 from 1 broker.
    Wockhardt To Exit US Generic Business; Focus On Antibiotics, Diabetes Care
    NDTV Profit | 13 Jul 2025
    logo
    Novartis India Ltd.
    14 Jul 2025
    918.10
    -0.01%
    Divi's Labs Shares Slide After Novartis' Entresto Loses Patent Lawsuit
    Divi's Labs Shares Slide After Novartis' Entresto Loses Patent Lawsuit
    NDTV Profit
    Divi's Labs makes active pharmaceutical ingredients for Entresto for Novartis, which contributes nearly 8% to Hyderabad-based drugmaker's revenue.
    Copy LinkShare onShare on Share on Share on
    Novartis India Ltd. is trading below all available SMAs
    logo
    Anthem Biosciences Ltd.
    14 Jul 2025
    833.50
    1.53%
    Anthem Biosciences issue opens today in a price band of 540-570
    Business Line
    Mobilised 1,016-cr from anchor investors on Friday
    Copy LinkShare onShare on Share on Share on
    Anthem Biosciences Ltd. has gained 46.23% in the last 1 Year
    logo
    Sigachi Industries Ltd.
    14 Jul 2025
    Dividend High Gain High Volume Insider Trades
    42.87
    13.71%
    Sigachi's lessons: A red line on safety for pharma manufacturing units
    Business Line
    Telangana and Andhra Pradesh attempt a course correction, but is it enough?
    Copy LinkShare onShare on Share on Share on
    Sigachi Industries Ltd. is trading above its 150 day SMA of 41.2
    logo
    Cipla Ltd.
    13 Jul 2025
    1574.60
    0.88%
    Cipla To Take On Eli Lilly, Novo Nordisk With Entry Into India's Weigh-Loss Drug Sector
    Cipla To Take On Eli Lilly, Novo Nordisk With Entry Into India's Weigh-Loss Drug Sector
    NDTV Profit
    Cipla is preparing to enter the weight-loss drug making sector, heating the competition with US-based Eli Lilly & Co and Danish firm Novo Nordisk.
    Copy LinkShare onShare on Share on Share on
    Deven Choksey released a Hold report for Cipla Ltd. with a price target of 1570.0 on 08 Sep, 2025.
    Cipla gears up to enter weight management segment in India
    Business Line | 13 Jul 2025 1 more
    Cipla to enter weight management segment in India: MD & Global CEO Vohra
    Business Standard | 13 Jul 2025
    logo
    Glenmark Pharmaceuticals Ltd.
    12 Jul 2025, 07:53AM
    Dividend
    2132.50
    0.23%
    Glenmark surges 20% after major drug licensing deal with AbbVie
    Glenmark surges 20% after major drug licensing deal with AbbVie
    Economic Times
    Glenmark Pharmaceuticals shares surged following a significant licensing agreement. Ichnos Glenmark Innovation partnered with AbbVie for a drug targeting oncology and autoimmune diseases. Glenmark will receive $700 million upfront. Potential milestone payments could reach $1.2 billion. Future sales will also generate revenue for Glenmark. Analysts predict a positive re-rating of the stock due to this deal.
    Copy LinkShare onShare on Share on Share on
    Geojit BNP Paribas increased Accumulate price target of Glenmark Pharmaceuticals Ltd. to 2306.0 on 09 Sep, 2025.
    logo
    Wockhardt Ltd.
    11 Jul 2025, 09:04PM
    1518.00
    -0.61%
    Wockhardt exits US generics biz, to focus on innovative portfolio
    Business Standard
    Wockhardt exits the US generics market after years of losses, shifting focus to new antibiotic drug discovery and biologicals, including insulin, to create long-term value.
    Copy LinkShare onShare on Share on Share on
    Wockhardt Ltd. has gained 51.72% in the last 1 Year
    Wockhardt to exit its US generics business
    Business Line | 11 Jul 2025, 07:59PM 1 more
    Wockhardt exits US generics business, files for liquidation of subsidiaries
    Business Standard | 11 Jul 2025, 05:53PM
    logo
    Glenmark Pharmaceuticals Ltd.
    11 Jul 2025, 10:09AM
    Dividend
    2132.50
    0.23%
    Glenmark Pharma soars 10%, hits 52-week high on cancer drug licensing deal
    Business Standard
    At 09:30 AM, Glenmark Pharma shares were trading at 2,094.40, up by 10 per cent on the National Stock Exchange.
    Copy LinkShare onShare on Share on Share on
    Glenmark Pharmaceuticals Ltd. is trading above all available SMAs
    Glenmark Pharma Shares Hit Life High After License Deal With AbbVie For Cancer Drug
    NDTV Profit | 11 Jul 2025, 09:47AM 4 more
    Glenmark Share Price Live: Glenmark Pharma locked in upper circuit after its arm's mega ISB 2001 deal
    Business Line | 11 Jul 2025, 09:44AM
    Glenmark Pharma's Mega Deal With AbbVie Has Brokerages Mixed
    NDTV Profit | 11 Jul 2025, 09:25AM
    Glenmark subsidiary IGI inks $700-m deal on cancer drug candidate with multinational AbbVie
    Business Line | 10 Jul 2025
    Glenmark Pharma's unit, Abbvie sign global licensing deal for cancer drug
    Business Standard | 10 Jul 2025
    more
    loading
    Logo Trendlyne

    Stay ahead of the market

    Company

    PrivacyDisclaimerTerms of Use Contact Us

    Resources

    Blog FAQsStock Market Widgets

    Copyright © 2025 Giskard Datatech Pvt Ltd